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summer but the data are suggestive, and Japan may be
one of the few cultures where further results on the
relative success of living-related donors for islet
transplantation could be garnered.
Some cautionary notes should be sounded. Insulin
independence is now being reported with single organs
from cadaveric donors.7 More importantly, the report by
Matsumoto and colleagues does not explore the issue of
islet survival. Transplant programmes of type 1 islets
from cadaveric donors have reported outcomes after
long periods of insulin independence in the recipient—
perhaps a year.2,7 Islet survival after transplantation
might not be indefinite—it is unclear whether late islet
loss is because of rejection, failure of regeneration and
repair in the extrapancreatic site, or recurrence of
autoimmune diabetes. If islet loss is because of
recurrence of autoimmune diabetes, the data from
Matsumoto’s patients will not be readily applicable to
the population with type 1 disease. If islet loss is not
because of recurrence, the benefits of temporary insulin
independence for the patient must be weighed against
the health risk to the surviving donor. Protection from
severe hypoglycaemia in the Edmonton series of
patients persists beyond insulin independence. Against
that, the donor in Matsumoto’s study had a significant
operation and exposed herself to increased risk of
diabetes, as a result of the loss of part of her own
pancreas.8
It is estimated that up to 25% of patients with type 1
diabetes are susceptible to recurrent severe hypo-
glycaemia.9 Of these patients, perhaps 15% cannot be
substantially improved by proper manipulation of
conventional therapy. For them, transplantation—be
it of whole organ as the Americans recommend,10 or
islet transplantation as currently clinically available in
Canada11—can and should be available. But to render
islet transplantation an appropriate therapy for more
people with insulin-deficient diabetes, we need ways
of improving islet recovery and survival after the
transplantation, and much more specifically targeted
immunosuppression. In societies in which trans-
plantation of cadaveric organs is feasible, the use
of living, related donors seems difficult to justify.
Matsumoto’s group is in a position to ethically explore
whether such donors can safely provide more robust
successes, and the diabetes world should watch their
progress with great interest.
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Maternal hypothyroxinaemia during (early) gestation
Brain development is strongly dependent on an
adequate supply of thyroid hormone. Because the fetal
thyroid cannot produce thyroxine until mid-gestation,
the fetus is totally dependent on thyroxine that
originates from the mother.1 In other words, mental and
motor skills in later life depend on the integrity of the
maternal thyroid and its regulatory system, and an
adequate maternal supply of iodine (the unique and
essential substrate for thyroid hormone) during
gestation. However, there is no consensus about
whether level of the maternal free thyroxine
concentration or the maternal thyroid-stimulating
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hormone (thyrotropin, TSH) during gestation should be
the main determinant to verify adequacy of the
thyroxine supply to the fetal brain.
Recently, Hossein Gharib and Martin Surks and their
respective colleagues2,3 gave their views about screening
and treatment of subclinical thyroid dysfunction on
statements made previously by an expert panel of the
American Association of Clinical Endocrinologists, the
American Thyroid Association, and the Endocrine
Society.4 For the consequences of subclinical hypo-
thyroidism (ie, increased TSH with free thyroxine within
its reference range) during pregnancy, the clinicians’
view2 favours screening by TSH measurement during or
even before gestation, while the evidence-based
approach disagrees.3 No comments were made about
gestational hypothyroxinaemia (ie, free thyroxine below
the 5th or 10th percentile with TSH within its reference
range), although an association between this condition
and impaired infant (neuro)development has repeatedly
been shown.1 A relation with attention deficit and
hyperactivity disorders also has been suggested.5 The
expert panel defined (non-pregnant) reference ranges as
0·45–4·5 mIU/L for TSH and 10·3–25·7 pmol/L for free
thyroxine.4 However, a 20-year follow-up in the general
population showed that TSH levels over 2·0 mIU/L
increases the risk of future overt thyroid dysfunction,
suggesting that above this level thyroid functioning is
already compromised.6
Which reference ranges should be used throughout
pregnancy? Because the placental hormone chorionic
gonadotropin (HCG) is a weak thyroid stimulator, first-
trimester maternal TSH values should be interpreted
cautiously. When iodine supply is insufficient, changes
in thyroid hormone concentrations might occur without
changes in TSH.1 Finally, it should be remembered that
maternal TSH is unable to pass the placenta throughout
pregnancy, which questions the implications of elevated
maternal TSH levels for the fetus when simultaneous
maternal levels of free thyroxine are still above the cut-
off for hypothyroxinaemia. The 10th percentile level for
free thyroxine of 11–12 pmol/L in early gestation
decreases to 9–10 pmol/L in late gestation.7 Women
with subclinical hypothyroidism during gestation often
have free thyroxine concentrations above these cut-
offs. We still do not know why levels of free thyroxine
gradually decrease with increasing term. However, we
have to keep in mind that assessments of free thyroxine
are sensitive to aberrant concentrations of thyroid-
hormone binding protein, such as the elevated
concentrations of thyroxine-binding globulin during
pregnancy.8 Also, iodine intake influences free thyroxine
levels. During the past decade, it has been hypothesised
that women living in iodine sufficient or repleted areas
are still at risk of iodine deficiency when they become
pregnant, because then their iodine requirements
almost double.9 There is no discussion about the major
negative effect both on pregnancy and neonatal
outcome in areas with severe iodine deficiency.
However, a recent meta-analysis of six European
placebo-controlled studies, in which pregnant women
living in areas with marginally sufficient iodine intake
and supplemented with various doses of iodine, showed
that there was hardly any effect on their thyroid
hormone levels during gestation.10 So, the assumption
of a direct relation in these areas between iodine intake
and maternal levels of free thyroxine might be too
simple. What is urgently needed are valid gestational
reference ranges for serum TSH and free thyroxine,
especially in women whose thyroids are not
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compromised by autoimmune diseases (as reflected by
the absence of circulating thyroid antibodies) and with a
definitely proven sufficient intake of iodine.8
“Dear colleague, I am a physician from the US. I am
pregnant now for 12 weeks, and my free thyroxine was
11 pmol/L. Would you be in favour of an abortion in
order not to have a child with impaired neurodevelop-
ment?” Over the past 12 months, we have received over
a dozen e-mails from all over the world with similar
questions. Even endocrinologists have asked for advice
because they did not agree with gynaecologists who
recommended their pregnant patients consider abortion
because of hypothyroxinaemia during early gestation.
Children of pregnant women with subclinical
hypothyroidism can benefit from thyroxine treatment
during gestation.11 Moreover, a 2-year follow-up of
children born to women with hypothyroxinaemia during
early gestation showed no (neuro)developmental delay
in the children whose mothers presented with
(spontaneously) increasing levels of free thyroxine after
the first trimester.7 Placebo-controlled intervention
studies in pregnant women with subclinical hypothy-
roidism or hypothyroxinaemia are needed to evaluate
the effect of thyroxine administration on the (neuro)-
development of the offspring. Careful monitoring of
iodine intake during gestation, lactation, and the first
2–3 years of life will be needed.
As Surks and colleagues state,3 the crux of the
evidence-based approach is that “the physician will do no
harm”. How can a clinician deal with this issue against the
background that until now we do not know which
determinant of thyroid function (free thyroxine or TSH)
is most appropriate for screening purposes, which
reference ranges should be used, which condition
(hypothyroxinaemia or subclinical hypothyroidism) has
the worse outcome and for whom (fetus vs mother), and
what the confounding role is of individual iodine
supplementation in populations with suboptimum
iodine intake? Obviously, there is no evidence-based
argument to advise hypothyroxinaemic women to have
an abortion, but how do we deal with the risk of impaired
neurodevelopment? The explained variance of impaired
neurodevelopment due to hypothyroxinaemia is
reported as 5–18% (which means that by far the majority
of variance is not attributable to maternal level of free
thyroxine). Nevertheless it would be best, for women
with low levels of free thyroxine (12 pmol/L) during
early gestation, even without elevated TSH, to supply
thyroxine to keep their free thyroxine in the middle or
upper range.
For clinicians, even the more scientifically rigorous
members of the above-mentioned expert panel
recommend treatment with thyroxine for pregnant
women with subclinical hypothyroidism. Although there
are no intervention trials published to support this
recommendation, these experts argued that the
potential benefit-risk ratio justifies this approach: the
chances of harm when appropriately managed (including
monthly monitoring of the maternal thyroid function)
are minimum.4 On the basis of the same arguments, we
believe that also correcting isolated low levels of free
thyroxine by supplementation with thyroxine would be
good advice about how to deal with gestational
hypothyroxinaemia.
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